Clinical Trial Sites

Investigator sites and clinical research units — running trials to Good Clinical Practice, protecting subjects, and generating the source data a submission is built on.

What this page does not claim

A sector is an organization’s role in the value chain, not a legal category. SPEQ maps the disciplines and standards that role typically operates under; it does not determine which apply to your organization, and a count of decoded standards measures SPEQ’s coverage.

WHAT THIS SECTOR DOES

Clinical trial sites — hospitals, dedicated research units, and investigator offices — are where a study actually meets patients. They enroll and protect subjects, execute the protocol, and generate the source data on which the entire submission ultimately rests. The credibility of a marketing application depends on what happens, and what is recorded, at the site.

REGULATORY LANDSCAPE

Sites operate to Good Clinical Practice (ICH E6(R3), building on E8(R1) study design), under FDA 21 CFR Parts 312, 50, and 56 and, in the EU, the Clinical Trials Regulation (536/2014). Subject safety runs through informed consent and IRB/ethics-committee oversight, and adverse events feed pharmacovigilance under ICH E2A and EU GVP. Source data and electronic systems carry ALCOA+ and 21 CFR Part 11 expectations.

THE OVERSIGHT MODEL

The site works under the sponsor and its monitors but is led by a principal investigator who is personally accountable for the conduct of the trial and the safety of subjects. The sponsor provides the protocol and performs risk-based monitoring; the ethics committee/IRB safeguards subjects; and the investigator ensures the protocol is followed and the data are attributable and accurate. Accountability is shared, but subject protection sits squarely with the site.

WHAT QUALITY MEANS HERE

01

Subject safety & informed consent

Valid, documented informed consent and IRB/ethics oversight — the ethical foundation without which no data are usable.

02

Protocol adherence

Following the approved protocol and documenting any deviation, so the data mean what the analysis assumes they mean.

03

Source data & ALCOA+

Attributable, legible, contemporaneous, original, accurate source records — the evidence a monitor and inspector reconstruct the trial from.

04

Safety reporting

Timely identification and reporting of adverse events to the sponsor and, as required, to authorities under the expedited-reporting clock.

30
Standards decoded
2
GxP disciplines

STANDARDS SPEQ DECODES · 30

Open the full library →
ICH E6(R3)ICHHIGH INSPECTION RISK
Good Clinical Practice (GCP)
ICH E8(R1)ICH
General Considerations for Clinical Studies
21 CFR Part 312FDAHIGH INSPECTION RISK
Investigational New Drug Application (IND)
21 CFR Part 50FDAHIGH INSPECTION RISK
Protection of Human Subjects (Informed Consent)
21 CFR Part 56FDA
Institutional Review Boards (IRBs)
Regulation (EU) 536/2014EMAHIGH INSPECTION RISK
Clinical Trials Regulation (CTR)
EU GVP ModulesEMAHIGH INSPECTION RISK
EU Good Pharmacovigilance Practices (GVP)
21 CFR 314.80FDAHIGH INSPECTION RISK
Postmarketing Reporting of Adverse Drug Experiences
ICH E2B(R3)ICH
Electronic Transmission of Individual Case Safety Reports (ICSRs)
ICH E2AICH
Clinical Safety Data Management: Definitions and Standards for Expedited Reporting
VICH GL9VICH
Good Clinical Practice (Veterinary)
21 CFR Part 803FDAHIGH INSPECTION RISK
Medical Device Reporting (MDR)
ICH M10ICHHIGH INSPECTION RISK
Bioanalytical Method Validation and Study Sample Analysis
ISO 20916:2019ISO
In vitro diagnostic medical devices — Clinical performance studies using specimens from human subjects
ICH E9(R1)ICHHIGH INSPECTION RISK
Statistical Principles for Clinical Trials, incl. Addendum on Estimands and Sensitivity Analysis
ICH E3ICHHIGH INSPECTION RISK
Structure and Content of Clinical Study Reports
ICH E2C(R2)ICHHIGH INSPECTION RISK
Periodic Benefit-Risk Evaluation Report (PBRER)
ISO 14155:2026ISOHIGH INSPECTION RISK
Clinical Investigation of Medical Devices for Human Subjects — Good Clinical Practice
ISO 15189:2022ISOHIGH INSPECTION RISK
Medical Laboratories — Requirements for Quality and Competence
ICH E2D(R1)ICH
Post-Approval Safety Data: Definitions and Standards for Management and Reporting of Individual Case Safety Reports
Reg. (EU) 520/2012ECHIGH INSPECTION RISK
Commission Implementing Regulation on the Performance of Pharmacovigilance Activities
21 CFR 600.80FDAHIGH INSPECTION RISK
Postmarketing Reporting of Adverse Experiences (Biological Products)
VICH GL24VICH
Pharmacovigilance of Veterinary Medicinal Products: Management of Adverse Event Reports (AERs)
ICH E2EICH
Pharmacovigilance Planning
42 CFR Part 493CMSHIGH INSPECTION RISK
Laboratory Requirements (CLIA)
EMA/INS/GCP/532137/2010EMA
Reflection Paper for Laboratories That Perform the Analysis or Evaluation of Clinical Trial Samples
ISO/IEC 27001:2022ISO
Information Security, Cybersecurity and Privacy Protection — Information Security Management Systems — Requirements
Regulation (EU) 2016/679EC
General Data Protection Regulation (GDPR)
ISO 31000:2018ISO
Risk Management — Guidelines
WHO LBM 4th ed. (2020)WHO
Laboratory Biosafety Manual, Fourth Edition

WHERE QUALITY FAILS

  • Informed-consent or IRB/ethics failures that invalidate a subject’s data
  • Protocol deviations that go undocumented or unexplained
  • Source-data gaps that prevent reconstruction of what happened at the visit
  • Adverse events identified or reported late against the required timeline

KEY REGULATORY BODIES

Derived from the 30 standards SPEQ decodes for this sector.

Clinical Trial Sites: frequently asked questions

Reference answers on what a clinical trial sites does, what governs it, and who is accountable for quality.

What is a clinical trial site?

A clinical trial site — a hospital, dedicated research unit, or investigator office — is where a study meets patients. It enrolls and protects subjects, executes the protocol, and generates the source data on which the entire submission rests. The credibility of a marketing application depends on what happens, and what is recorded, at the site.

Which regulations govern a clinical trial site?

Sites operate to Good Clinical Practice (ICH E6(R3), building on E8(R1) study design), under FDA 21 CFR Parts 312, 50, and 56, and in the EU the Clinical Trials Regulation 536/2014. Subject safety runs through informed consent and IRB/ethics-committee oversight; adverse events feed pharmacovigilance under ICH E2A and EU GVP; source data carries ALCOA+ and 21 CFR Part 11 expectations.

Who is accountable for the conduct of a trial at the site?

The site works under the sponsor and its monitors but is led by a principal investigator who is personally accountable for the conduct of the trial and the safety of subjects. The sponsor provides the protocol and performs risk-based monitoring; the ethics committee/IRB safeguards subjects; and the investigator ensures the protocol is followed and the data are attributable and accurate.